Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, offering a new treatment option for cardiovascular protection. Sotagliflozin, a re ...
Type 1 diabetics have a lower risk of experiencing a cardiovascular event such as a stroke or heart attack than type 2 diabetics, a new study has found. It highlights the fundamental difference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback